Paris, 28 November 2022,

Kadans Science Partner has acquired a first site in Villejuif from SADEV 94 with a view to constructing a building dedicated to research and innovation.

The building of approximately 25,000 m2 will accommodate companies and institutions specialising in research, innovation and development in the field of health, particularly cancer. Located in the heart of the ZAC Campus Grand Parc, supported by SADEV 94 and Le Grand Orly Seine Bièvre area, opposite the Gustave Roussy Institute and directly linked to the Paris Saclay Cancer Cluster (PSCC) initiative, it will be operational in 2025.

Kadans Science Partner, a European creator of environments dedicated to innovation in the life sciences, is making its first real estate acquisition in France from SADEV 94 in Villejuif, and is unveiling its ambitious project for an R&D building at the heart of the Paris Saclay Cancer Cluster. It will be located less than 200 metres from metro lines 14 and 15, both of which are scheduled to be extended and opened from 2024.

Kadans Science Partner obtained a building permit this summer, which has since become final, for a multi-occupancy complex for private and public research and innovation players. Designed by the architectural firms Baumschlager Eberle and Same, the building is designed to provide all the conditions required for future occupants to carry out their R&D projects and develop their activities.

This new specialised rental offer will provide highly technical laboratories for companies of all sizes and will give access to flexible services, a wide range of services, including conference spaces, coworking spaces, meeting rooms, but also convivial spaces, green areas, terraces and gardens in the heart of the campus.

Elsa Ferrard, Director France of Kadans Science Partner, said: “We are very pleased to launch Kadans Science Partner’s activities in France with a first acquisition from SADEV 94 allowing such a large-scale project in Villejuif. Thanks to this building dedicated to supporting innovative companies, we will be able to provide a technical response to the specific needs of these companies, but above all we will facilitate the integration of project leaders into a dynamic ecosystem at the service of cancer research. This first opening in France is part of Kadans’ European strategy to create and federate a network of players at the service of innovation and research.

Christophe Richard, Managing Director of Sadev 94, said: “This sale reinforces the conviction of Sadev 94 and local elected officials, which is becoming more and more obvious: Campus Grand Parc is the place to make French oncology shine on an international scale. It is a fertile hospital ground for innovation, research and care dedicated to the fight against cancer. As a developer, we are committed to ensuring that this programmatic ambition takes shape in an inclusive neighbourhood, attentive to the well-being of its residents, professionals, patients and their families.

This acquisition was carried out with the Cheuvreux law firm, the legal support of the GALM law firm and the technical support of Sedri for Kadans Science Partner, the Dix Sept 68 notary office for SADEV 94 and with the support of Choose Paris Region.